WO2009129983A1 - Sels d'addition avec des acides de prasugrel et compositions pharmaceutiques les comprenant - Google Patents

Sels d'addition avec des acides de prasugrel et compositions pharmaceutiques les comprenant Download PDF

Info

Publication number
WO2009129983A1
WO2009129983A1 PCT/EP2009/002871 EP2009002871W WO2009129983A1 WO 2009129983 A1 WO2009129983 A1 WO 2009129983A1 EP 2009002871 W EP2009002871 W EP 2009002871W WO 2009129983 A1 WO2009129983 A1 WO 2009129983A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
prasugrel
sulfonic acid
acid addition
salt
Prior art date
Application number
PCT/EP2009/002871
Other languages
English (en)
Inventor
Ramesh Matioram Gidwani
Vikas S. Wakchaure
Original Assignee
Ratiopharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ratiopharm Gmbh filed Critical Ratiopharm Gmbh
Publication of WO2009129983A1 publication Critical patent/WO2009129983A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Abstract

L'invention porte sur des sels d'addition avec des acides de Prasugrel, sur un procédé pour leur fabrication et sur des compositions pharmaceutiques les comprenant. En particulier, l'invention porte sur des sels de Prasugrel avec des acides benzènesulfonique et naphtalènesulfonique.
PCT/EP2009/002871 2008-04-21 2009-04-20 Sels d'addition avec des acides de prasugrel et compositions pharmaceutiques les comprenant WO2009129983A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN975CH2008 2008-04-21
IN975/CHE/2008 2008-04-21

Publications (1)

Publication Number Publication Date
WO2009129983A1 true WO2009129983A1 (fr) 2009-10-29

Family

ID=40904043

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/002871 WO2009129983A1 (fr) 2008-04-21 2009-04-20 Sels d'addition avec des acides de prasugrel et compositions pharmaceutiques les comprenant

Country Status (1)

Country Link
WO (1) WO2009129983A1 (fr)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2469883A (en) * 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
WO2011127300A1 (fr) 2010-04-08 2011-10-13 Teva Pharmaceutical Industries Ltd. Formes cristallines de sels de prasugrel
EP2377520A1 (fr) 2010-03-24 2011-10-19 Ratiopharm GmbH Composition pharmaceutique du prasugrel
CZ302796B6 (cs) * 2009-11-16 2011-11-16 Zentiva, K. S. Cyklamát 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jeho výroby
US8193358B2 (en) 2006-04-06 2012-06-05 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
CN102532161A (zh) * 2012-02-27 2012-07-04 扬州市星斗药业有限公司 普拉格雷苯磺酸盐及其制备方法
WO2013010502A1 (fr) * 2011-07-21 2013-01-24 四川海思科制药有限公司 Sel d'addition d'acide de prasugrel, son procédé de préparation et utilisation
CN103304577A (zh) * 2012-03-07 2013-09-18 辽宁亿灵科创生物医药科技有限公司 普拉格雷酸加成盐及其制备方法和药物应用
WO2013150322A1 (fr) 2012-04-02 2013-10-10 Egis Pharmaceuticals Public Limited Company Compositions pharmaceutiques orales stables à libération immédiate et contenant du prasugrel
CN103772408A (zh) * 2012-10-26 2014-05-07 江苏先声药物研究有限公司 普拉格雷-1,5-萘二磺酸盐的结晶
CN103848844A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 普拉格雷成盐化合物及其制备方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542411A2 (fr) * 1991-09-09 1993-05-19 Sankyo Company Limited Dérivés de tétrahydrothieno-, und Pyrrolopyridinderivate, ihre Herstellung und Verwendung als Blutplättchen-Aggregation-Inhibitoren
EP1298132A1 (fr) * 2000-07-06 2003-04-02 Sankyo Company, Limited Sels d'addition acides de d riv s hydropyridine
WO2007114526A1 (fr) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Procede de production de prasugrel de grande purete et sel d'addition d'acide de celui-ci
WO2009062044A2 (fr) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Procédés de préparation de prasugrel et ses sels et polymorphes
WO2009066326A2 (fr) * 2007-11-19 2009-05-28 Msn Laboratories Limited Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0542411A2 (fr) * 1991-09-09 1993-05-19 Sankyo Company Limited Dérivés de tétrahydrothieno-, und Pyrrolopyridinderivate, ihre Herstellung und Verwendung als Blutplättchen-Aggregation-Inhibitoren
EP1298132A1 (fr) * 2000-07-06 2003-04-02 Sankyo Company, Limited Sels d'addition acides de d riv s hydropyridine
WO2007114526A1 (fr) * 2006-04-06 2007-10-11 Daiichi Sankyo Company, Limited Procede de production de prasugrel de grande purete et sel d'addition d'acide de celui-ci
EP2003136A1 (fr) * 2006-04-06 2008-12-17 Daiichi Sankyo Company, Limited Procede de production de prasugrel de grande purete et sel d'addition d'acide de celui-ci
WO2009062044A2 (fr) * 2007-11-09 2009-05-14 Dr. Reddy's Laboratories Ltd. Procédés de préparation de prasugrel et ses sels et polymorphes
WO2009066326A2 (fr) * 2007-11-19 2009-05-28 Msn Laboratories Limited Procédé amélioré pour la préparation de prasugrel et de ses sels pharmaceutiquement acceptables

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
BASTIN R J ET AL: "Salt Selection and Optimisation for Pharmaceutical New Chemical Entities", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, CAMBRIDGE, GB, vol. 4, no. 5, 1 January 2000 (2000-01-01), pages 427 - 435, XP002228592 *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8193358B2 (en) 2006-04-06 2012-06-05 Daiichi Sankyo Company, Limited Process for producing high-purity prasugrel and acid addition salt thereof
GB2469883A (en) * 2009-04-30 2010-11-03 Sandoz Ag Novel crystalline form of Prasugrel hydrogensulphate
CZ302796B6 (cs) * 2009-11-16 2011-11-16 Zentiva, K. S. Cyklamát 5-[2-cyklopropyl-1-(2-fluorfenyl)-2-oxoethyl]-4,5,6,7-tetrahydrothieno[3,2-c]pyridin-2-yl acetátu známého pod nechráneným názvem prasugrel a zpusob jeho výroby
EP2377520A1 (fr) 2010-03-24 2011-10-19 Ratiopharm GmbH Composition pharmaceutique du prasugrel
US8802854B2 (en) 2010-04-08 2014-08-12 Teva Pharmaceutical Industries Ltd. Crystalline forms of Prasugrel salts
WO2011127300A1 (fr) 2010-04-08 2011-10-13 Teva Pharmaceutical Industries Ltd. Formes cristallines de sels de prasugrel
EP2883877A1 (fr) 2010-04-08 2015-06-17 Teva Pharmaceutical Industries, Ltd. Formes cristallines de sels de prasugrel
US9012641B2 (en) 2010-04-08 2015-04-21 Teva Pharmaceuticals Industries Ltd. Crystalline forms of Prasugrel salts
WO2013010502A1 (fr) * 2011-07-21 2013-01-24 四川海思科制药有限公司 Sel d'addition d'acide de prasugrel, son procédé de préparation et utilisation
CN102532161A (zh) * 2012-02-27 2012-07-04 扬州市星斗药业有限公司 普拉格雷苯磺酸盐及其制备方法
CN103304577A (zh) * 2012-03-07 2013-09-18 辽宁亿灵科创生物医药科技有限公司 普拉格雷酸加成盐及其制备方法和药物应用
US8603537B2 (en) 2012-04-02 2013-12-10 Egis Pharmaceuticals Plc Prasugrel containing quickly released stable oral pharmaceutical compositions
WO2013150322A1 (fr) 2012-04-02 2013-10-10 Egis Pharmaceuticals Public Limited Company Compositions pharmaceutiques orales stables à libération immédiate et contenant du prasugrel
CN103772408A (zh) * 2012-10-26 2014-05-07 江苏先声药物研究有限公司 普拉格雷-1,5-萘二磺酸盐的结晶
CN103848844A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 普拉格雷成盐化合物及其制备方法

Similar Documents

Publication Publication Date Title
WO2009129983A1 (fr) Sels d'addition avec des acides de prasugrel et compositions pharmaceutiques les comprenant
US7915423B2 (en) Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US7439373B2 (en) Crystalline mycophenolate sodium
US11608318B2 (en) Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
CN113993853A (zh) 氯苯唑酸及其盐的固态形式
WO2017221189A1 (fr) Procédé amélioré pour la préparation de ténofovir alafénamide ou de sels pharmaceutiquement acceptables de celui-ci
US20040242556A1 (en) Novel crystalline form of cefdinir
US20210292479A1 (en) Solid state forms of sugammadex sodium
US20230057197A1 (en) Solid state forms of mavacamten and process for preparation thereof
WO2021236709A1 (fr) Formes à l'état solide de tapinarof
EP1507531B1 (fr) Compositions pharmaceutiques stables de desloratadine
US20220135548A1 (en) Solid state forms of n-[2-(2-{4-[2-(6,7-dimethoxy-3,4-dihydro-2(1h)-isoquinolinyl)ethyl]phenyl}-2h-tetrazol-5-yl)-4,5- dimethoxyphenyl]-4-oxo-4h-chromene-2-carboxamide and of its mesylate salt
US20230058102A1 (en) Solid state forms of blarcamesine salts
US11465974B2 (en) Crystalline polymorphs of Pracinostat and Pracinostat salts
US20220220149A1 (en) Solid state forms of sage-217 and processes for preparation thereof
EP1768969B1 (fr) Mycophenolate de sodium cristallin
WO2023022896A1 (fr) Polymorphes de ponésimod
WO2024100601A1 (fr) Formes à l'état solide de belumosudil et leurs procédés de préparation
WO2022081502A1 (fr) Formes à l'état solide de lorécivivint

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09734379

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09734379

Country of ref document: EP

Kind code of ref document: A1